Sirona Biochem (SBM:tsxv) receives approval to trade on Xetra
SIRONA BIOCHEM APPOINTS GERMAN PRIVATE BANK HAUCK & AUFHAUSER AS DESIGNATED SPONSOR FOR XETRA(R)
Sirona Biochem Corp.’s (SBM:tsxv) shares have been accepted for continuous trading on the German electronic trading platform Xetra under the ticker symbol ZSB.DE. The International Security Identification Number (ISIN) is CA82967M1005.
The electronic trading system Xetratrademarkis utilized to trade approximately 300,000 international instruments. Xetratrademarkhas a market share of over 90 percent in equity trading and is one of the fastest trading systems in the world with a round-trip-time at only two milliseconds. Financial institutions, securities trading houses and brokers can participate in Xetratrademark trading. Xetratrademark operates independently of the trader’s location, permitting international participation. In fact, more than 130 participants from European countries outside Germany trade on Xetratrademark.
Sirona Biochem has appointed Hauck & Aufhauser Privatbankiers KGaA (H&A) as its designated sponsor on Xetratrademark. The designated sponsor will work to facilitate higher liquidity in stock trading of Sirona common shares by maintaining a constant quotation volume (minimum trade volume) to ensure tradability is guaranteed — even in highly volatile market periods.
Dr. Howard Verrico, CEO and Chairman of Sirona Biochem, stated, “The Xetratrademark listing marks a further step in Sirona’s commitment to its shareholders to enhance the liquidity of the Company’s common shares and is one of many initiatives we are taking to further increase market awareness. A generally visible valuation discount due to limited liquidity will be reduced and therefore should generate an increased interest of institutional investors. Several potential European investors have confirmed that a continuous Xetratrademark listing will make it easier for them to invest in Sirona. We are proud that, from our point of view, the best Xetratrademark specialist team in Germany has chosen Sirona as a new client.”About Hauck & Aufhauser Privatbankiers KGaA
Hauck & Aufhauser Privatbankiers is one of the few independent private banks in Germany and can look back on over 219 years of tradition. The bank resulted from the 1998 merger of two highly traditional private banks: Georg Hauck & Sohn Bankiers, founded in Frankfurt am Main in 1796, and Bankhaus H. Aufhauser, which opened its doors in Munich in 1870.
From its locations in Frankfurt am Main, Munich, Hamburg, Dusseldorf and Cologne, the bank focuses on providing comprehensive advisory services and administering the assets of its private, corporate and institutional clients. This includes asset management for institutional investors, close cooperation with independent asset managers and both the concept and management of private label funds.
The partners of the bank consist of the personally liable partner, Jochen Lucht, and the partners, Michael O. Bentlage and Stephan Rupprecht. All of the bank’s capital is in the hands of private investors. Hauck & Aufhauser considers itself a private bank that combines modernity with a strong sense of tradition. The focus of its business activities is on providing comprehensive and personalized advisory services, which form the basis for developing customized solutions. For more information visit: www.hauck-aufhaeuser.de.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit: www.sironabiochem.com.
- Published in Blog, Business, Life Sciences
Amana Signs Definitive Agreement With IWS
Amana firms up deal to buy Int’l Wastewater for $6.3MM
Amana Copper Ltd. has signed a definitive agreement dated Sept. 4, 2015, with International Wastewater Systems Inc. and its shareholders, pursuant to which Amana will acquire 100 per cent of the issued and outstanding common shares of IWS.
Pursuant to the terms of the definitive agreement, on closing of the transaction: (i) Amana will issue to the IWS shareholders a total of 45 million Amana common shares at a deemed price of 14 cents per consideration share for total aggregate consideration of $6.3-million; (ii) the resulting issuer will be renamed International Wastewater Systems Inc. and will continue the business of IWS, a world leader in waste water heat exchange technology; (iii) management of the resulting issuer will be led by Lynn Mueller, chairman and chief executive officer, and Yaron Conforti, chief financial officer, and the board of directors will comprise Mr. Mueller, Mr. Conforti, Mark McCooey and Paul Lee.
All consideration shares will be subject to escrow conditions and/or resale restrictions, as required by applicable securities laws and Canadian Securities Exchange requirements. The transaction will constitute a fundamental change for the company pursuant to the policies of the CSE. It is expected that the company will obtain shareholder approval of the transaction by way of a shareholder consent resolution. The completion of the transaction is subject to shareholder approval, and CSE and regulatory approvals.
Additional information concerning IWS and the transaction will be provided in a CSE listing statement, which will be made available on the company’s SEDAR profile.
InMed Pharmaceuticals Appoints New CEO
InMed Appoints Paul Brennan as President & Chief Executive Officer
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
Craig Schneider, Director, states, “We are extremely pleased that at this critical stage in the Company’s development, Mr. Brennan will be taking the helm of InMed and leading the Company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive M&A, general management, financial, corporate and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed’s operations as we make progress toward delivering meaningful therapies to underserved markets.”
Mr. Brennan was previously Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals – NASDAQ). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed’s corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
InMed Pharma Starts Testing Drug Delivery System
InMed Commences Development of Proprietary Drug Delivery System
InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).
InMed’s development programs for transdermal delivery will use a nanoparticle-based delivery system. The delivery system underwent investigation in in vitro and in vivo animal models and further studies are being conducted based on the European norm “BS EN 13726-1: 2002” entitled test methods for wound dressings.
InMed anticipates commencing human proof of concept clinical studies of INM-750 in February, 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US Food and Drug Administration (FDA).
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
DealNet Announces Key Executive Appointments
DealNet Announces Key Executive Appointments: Roy Murzello as SVP of Consumer Finance Business and Michael Hilmer as CEO
DealNet Capital Corp. (“DealNet” or the “Company”) (TSX VENTURE: DLS) is pleased to announce that it has named Mr. Roy Murzello, a Consumer Lending Veteran with 15 years of experience, as its Senior Vice President of Consumer Financial Services.
Mr. Murzello has spent the last 10 years as a Senior Leader at one of Canada’s largest providers of HVAC finance solutions. His various roles have included Director of Dealer Programs, where Mr. Murzello was directly responsible for leading and growing the dealer finance programs including HVAC leasing. In this role, he also led a large leasing business that was acquired and subsequently integrated into the core business. His prior experience includes Vice President for Citi Group managing a major credit card initiative, a Senior Underwriter Manager at GE Capital and Credit Manager at CIBC. Mr. Murzello has a Master of Business Administration degree from Simon Fraser University.
“Roy’s pedigree is synonymous with large scale finance book management and risk mitigation. His experience with acquiring and operating large scale finance books, underpinned by strong governance and risk management fits our growth plans perfectly”, stated Michael Hilmer, Chief Executive Officer of DealNet.
The Company also appointed Mr. Michael Hilmer as its permanent Chief Executive Officer. Mr. Hilmer is a co-founder of DealNet and has served as the Company’s Interim CEO since March.
“Michael has performed at an exceptional level as Interim CEO and has earned our full confidence that he is the best choice for the CEO role” says Dr. Steven Small, Executive Chairman of the Corporation.
About DealNet Capital Corp.
DealNet is a consumer finance company that is initially focused on home improvement finance solutions including heating ventilation and air conditioning financing and leasing. DealNet leverages its large scale customer service and engagement technology platform to attract home improvement dealers by providing front and back office services to them resulting in dealer origination growth.
InMed Appoints Paul Brennan to the Board of Directors
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company’s Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
Mr. Brennan is currently Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“Paul’s extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will greatly complement and strengthen our Board,” said Craig Schneider, President and CEO of InMed. “We are delighted that he has accepted a position to the Board.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
InMed also wishes to announce it has accepted the resignation of Kevin Puil as a Director of the Company, effective today. The Board wishes to thank Mr. Puil for his efforts on behalf of the Company.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
Amana Copper (AMA:CSE) hires Momentum for IR
AMANA PROVIDES TRANSACTION UPDATE
Amana Copper Ltd. (AMA:CSE) is providing shareholders with an update on the company’s transaction with International Wastewater Systems (IWS), previously announced on June 5, 2015.
Amana and IWS are working diligently toward completion of the transaction. In preparation for closing the transaction, the company has reserved the stock symbol IWS with the Canadian Securities Exchange.
The company further announces that it has engaged Momentum Public Relations (MomentumPR) to provide investor and public relations services commencing Sept. 1, 2015. MomentumPR will assist the company in increasing public awareness by managing corporate communications and marketing activities, and facilitating dialogue with shareholders, the investment community and media contacts.
Max Gagne, president of MomentumPR, commented: “We are excited to team up with Amana and IWS, as they near completion of their proposed transaction. IWS is a world leader in state-of-the-art waste water heat recovery technology, with tremendous potential for revenue growth. MomentumPR has a particular focus on revenue-generating opportunities; we expect that IWS will be very well received by the investment community and will create great opportunities for our networks.”
InMed Announces Positive In-Vitro Study Results
InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.
Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “There are different sub-types of EBS caused by mutations of various keratin genes such as keratin 5, keratin 14 or keratin 15 etc. By modulating the expression of various keratin genes that are responsible for cytoskeleton intermediate filaments and/or wound healing using INM-750, we hoped to alleviate the EBS symptoms. Our preliminary results clearly validate this approach since INM-750 displayed modulation of expression of various keratin genes.”
Craig Schneider says, “We are very pleased that we have again demonstrated the ability and efficiency of our platform technology (“IDP”) to discover novel therapies in disease areas with large unmet medical needs. We have successfully employed our “IDP” for the discovery of INM-750 (see News Release May 26, 2015) which validates our in-silico approach to drug discovery by these positive pre-clinical results.”
InMed anticipates commencing human proof of concept clinical studies of INM-750 in February, 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US Food and Drug Administration (FDA).
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of Epidermolysis bullosa, a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and dermis, resulting in friction and skin fragility. Its severity ranges from mild to lethal. As of today there is no cure or effective treatment. Currently, wound care, pain management and preventative bandaging are the only options available for treatment.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
- Published in Blog, Life Sciences
Dundee Sustainable Technologies Inc.: Patent Notice of Allowance for Collection of Gold Over Silica
Dundee Sustainable Technologies Inc. (“DST” or the “Corporation”) (DST:CSE) is pleased to announce that the United States Patent and Trademark Office has issued a notice of allowance for DST patent application (number 13/957,002) pertaining to gold recovery over silica.
Collection of gold over silica
This patent is related to a method for recovering gold from a pregnant solution resulting from halogen leaching of an ore, while facilitating the recycling of the halogens from the resulting barren solution. The same patent is also pending in Canada and several Latin America countries.
An essential complement of gold extraction with halogens
This method has been proven well adapted to the halogens extraction process and a simple fusion of the loaded silica makes pure gold recovery easy and complete.
About Dundee Sustainable Technologies, a company controlled by Dundee Corporation
DST is engaged in the development of technologies for the treatment of refractory ores containing sulfides and arsenic. DST has developed proprietary hydrometallurgical processes, and owns the related patents, for the extraction of precious and base metals from ores, concentrates and tailings, which cannot be extracted with conventional processes because of metallurgical issues or environmental considerations.
DST’s patented approach provides a cyanide-free process to allow the exploitation of gold and other deposits that would otherwise face metallurgical issues with conventional methods. The primary benefits of the innovative technology are shorter processing times, a closed-loop operation eliminating the need for costly tailings pond, reduced environmental footprint related to inert and stable characteristics of the tailings, and lesser emissions due to lower energy consumption.
The process developed by DST is a recognized “green technology” for which it was awarded a $5.7 million grant towards the construction and operation of a $25 million demonstration plant. With a capacity of 15 tonnes per day of concentrate, the demonstration plant will serve as a proof of concept for the chlorination extraction technology on an industrial scale and under continuous operating conditions.
DST has tested several different gold deposits, both oxide and sulfide ores at the lab level and at its pilot plant. These tests have, consistently achieved gold recoveries in excess of 90{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, using chlorination instead of cyanide.
Tesla’s whole year depends on their ability to deliver
Tesla’s entire year hinges on answering one big question
Matthew DeBord – Business Insider
Tesla reports second-quarter earnings on Wednesday after the close and CEO Elon Musk will hold a conference call with analysts after the numbers are released.
We’ll be covering the earnings announcement and the call, so check back.
Everyone is going to want one huge question answered: Will Tesla be able to deliver 55,000 vehicles this year?
In the first half of the year, the company delivered less than half that total. So the pressure is on.
Tesla’s actual financials in the second-quarter are expected to be a downer.
According to the Wall Street Journal, Tesla lost money in the quarter — $117 million net, translating when adjusted to $0.59 per share.
Last year during the same period, Tesla made $0.11 per share.
In the second-quarter, Tesla is expected to see a big jump in review, to $1.17 billion, the Journal reported.
Tesla is spending a huge amount of money right now to expand operations and to develop and introduce new vehicles, as well as bring online a massive battery factory in Nevada and create an energy storage business.
So the combination of increasing revenue and declining profits shouldn’t surprise anyone. Musk and his team already informed the investment community that they’re prepared to spend a “staggering” amount to vindicate the company’s $33-billion market cap and lofty stock price.
There also won’t be much suspense around how may cars Tesla sold in the quarter. The company has begun reporting deliveries on a quarterly basis (the rest of the industry reports monthly), so we know that 11,507 vehicles made it to customers in Q2, a jump of 52{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} from last year. Combined with the first quarter, Tesla sold 21,537 vehicles through the first half of 2015.
Can Tesla build enough Model S sedans?
Everyone who follows Tesla is obsessed with whether the Model X crossover SUV will launch on schedule this quarter. But Model X sales aren’t expected to make a major contribution to Tesla’s 2015 goal — probably less than 5,000 vehicles, assuming the launch goes off without any hitches.
That means delivering over 25,000 Model S sedans by the end of the year is critical.
Last year, Tesla was able to build all the cars it said it would — 35,000 — but about a thousand deliveries slipped into the first month of 2015, and that weakness sent Tesla stock into a funk that it has since recovered from.
Investors will want to know if they’re in for a rehash of that script in 2015, so Musk’s comments on the earnings call will be more important than the earnings themselves. If he and Tesla’s leadership can confidently declare that 55,000 deliveries are in their sights, shares may not stage a retreat. But coming through on Model S deliveries while starting to roll Model X SUVs off the assembly line is a tall order. It’s uncharted territory for Tesla, which has effectively spent the past few years building one car.
AP
Tesla may have to run flat out for the next six months to meet its production and sales goals, but 55,000 vehicles still isn’t out of the question. However, if there are any indications of wavering on that target, Tesla could wind up being punished by the markets.
Other aspects of Tesla’s business will be copiously scrutinized on Wednesday — there will undoubtedly be a lot of questions about cyber-security in the aftermath of the hacking of a Jeep sold by Fiat Chrysler, especially since Tesla is the most wired of automakers — but executing on Model S through the remainder of 2015 is the biggie.
History lesson
It’s worth bringing a bit of history into the picture here. Tesla is building a new kind of car — all electric — and with the Model S and a lesser extent the Model X, aiming for an affluent buyer. The Model 3 mass-market car won’t arrive until 2017, at which point Tesla needs to producing cars much more quickly.
Production doesn’t have to be hard. When Ford introduced the Model T 100 years ago, production ramped up quite rapidly, roughly doubling every year before taking off in year five (1913).
Henry Ford’s mass-production techniques made this possible. So Ford wasn’t ever meaningfully constrained on the production side.
Tesla’s problem has always been production (demand for its vehicles, at least in the US, has historically been robust). This was understandable as the company established the Model S in the market. But now it’s starting to be a conundrum. Musk wants to build half a million cars by 2020. So why is his company still struggling to build 55,000 in 2015?
This is, after all, a car we’re talking about (we understand that Musk’s other company, SpaceX, builds rockets, which are slightly more difficult). Tesla is a startup by the standards of the auto industry, but other car makers seem to be able to assemble vehicles at a fierce clip. General Motors sold 272,512 in July alone.
Within the next 2-12 months, Tesla is going to need to reassure the world it can operate like a typical car company (even it wants to be seen as anything but typical) and meet established production objectives. This is where the auto industry is a pretty simply business: it’s hard to sell cars you can’t build. Musk is sensitive to making customers wait for new vehicles, so it’s reasonable to expect that he’ll be very focused on this challenge for the balance of 2015